REGENXBIO, Inc. (RGNX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159830,
    "name": "REGENXBIO, Inc.",
    "stock_name": "REGENXBIO, Inc.",
    "full_name": "REGENXBIO, Inc.",
    "name_url": "stocks-analysis/regenxbio-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "12.98",
    "chg": 0.77,
    "chgp": "6.31%",
    "dir": 1,
    "prev_price": "12.21",
    "mcapval": "478.87",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US75901B1070",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.88 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/regenxbio-inc-1159830-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "REGENXBIO, Inc. Hits New 52-Week High at $12.30",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/regenxbio-inc-hits-new-52-week-high-at-1230-3608013",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/REGENXBIOInc_priceRelatedfactors_3608013.png",
        "date": "2025-10-09 20:10:15",
        "description": "REGENXBIO, Inc. has achieved a new 52-week high of USD 12.30, significantly up from its low of USD 5.04. Despite this milestone, the company's one-year performance is down 10.87%. With a market cap of USD 479 million, REGENXBIO faces challenges, including negative return on equity and no dividend yield."
      },
      {
        "title": "Is REGENXBIO, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regenxbio-inc-technically-bullish-or-bearish-3546027",
        "imagepath": "",
        "date": "2025-09-20 19:23:22",
        "description": "As of 25 August 2025, the technical trend for REGENXBIO, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the weekly and monthly KST indicators show a mildly bearish stance. The Bollinger Bands indicate a bullish trend on the weekly chart but a mildly bearish trend on the monthly chart. Dow Theory reflects a mildly bullish outlook on the weekly basis, contrasting with a mildly bearish view on the monthly. The On-Balance Volume is mildly bearish for both weekly and monthly periods.\n\nIn terms of performance, REGENXBIO has a year-to-date return of 21.09%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the longer term, with a one-year return of -25.30% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the b..."
      },
      {
        "title": "Is REGENXBIO, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-regenxbio-inc-overvalued-or-undervalued-3542664",
        "imagepath": "",
        "date": "2025-09-20 17:58:54",
        "description": "As of 28 February 2023, the valuation grade for REGENXBIO, Inc. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.76 and an EV to Sales ratio of 1.76, which suggest that the market is pricing the stock higher than its underlying value. Additionally, the negative ROCE of -231.58% and ROE of -57.51% further highlight the company's struggles in generating returns for shareholders.\n\nIn comparison to peers, Keros Therapeutics, Inc. has a P/E ratio of 33.47, while Revance Therapeutics, Inc. shows a risky valuation with an EV to EBITDA of -4.03, underscoring the challenges faced by REGENXBIO. The company's stock has underperformed significantly over the long term, with a 5-year return of -68.75% compared to a 96.61% return for the S&P 500, reinforcing the notion that REGENXBIO i..."
      }
    ],
    "total": 8,
    "sid": "1159830",
    "stock_news_url": "https://www.marketsmojo.com/news/regenxbio-inc-1159830"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

REGENXBIO, Inc. Hits New 52-Week High at $12.30

2025-10-09 20:10:15

REGENXBIO, Inc. has achieved a new 52-week high of USD 12.30, significantly up from its low of USD 5.04. Despite this milestone, the company's one-year performance is down 10.87%. With a market cap of USD 479 million, REGENXBIO faces challenges, including negative return on equity and no dividend yield.

Is REGENXBIO, Inc. technically bullish or bearish?

2025-09-20 19:23:22

As of 25 August 2025, the technical trend for REGENXBIO, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the weekly and monthly KST indicators show a mildly bearish stance. The Bollinger Bands indicate a bullish trend on the weekly chart but a mildly bearish trend on the monthly chart. Dow Theory reflects a mildly bullish outlook on the weekly basis, contrasting with a mildly bearish view on the monthly. The On-Balance Volume is mildly bearish for both weekly and monthly periods. In terms of performance, REGENXBIO has a year-to-date return of 21.09%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the longer term, with a one-year return of -25.30% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the b...

Is REGENXBIO, Inc. overvalued or undervalued?

2025-09-20 17:58:54

As of 28 February 2023, the valuation grade for REGENXBIO, Inc. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.76 and an EV to Sales ratio of 1.76, which suggest that the market is pricing the stock higher than its underlying value. Additionally, the negative ROCE of -231.58% and ROE of -57.51% further highlight the company's struggles in generating returns for shareholders. In comparison to peers, Keros Therapeutics, Inc. has a P/E ratio of 33.47, while Revance Therapeutics, Inc. shows a risky valuation with an EV to EBITDA of -4.03, underscoring the challenges faced by REGENXBIO. The company's stock has underperformed significantly over the long term, with a 5-year return of -68.75% compared to a 96.61% return for the S&P 500, reinforcing the notion that REGENXBIO i...

View All News